Estelle
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
Description: 15mg E4 plus 3mg DRSP in an oral contraceptive.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Oral
Duration Type: Short-acting
Duration: One day
Dose: 15 mg E4, 3 mg DRSP
Active Pharmaceutical Ingredient (API): - estetrol (E4)
- drospirenone
- estetrol (E4)
- drospirenone
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Mithra
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase III
Began discovery in: 2001
Active Development: Yes
Status Details: - Ongoing phase III clinical trial on efficacy, safety, and acceptability of 15 mg E4 and 3 mg DRSP in the U.S. and Canada.
- Ongoing phase III clinical trial on efficacy, safety, and acceptability of 15 mg E4 and 3 mg DRSP in the U.S. and Canada.
Additional Information
References: Mithra Website: https://www.mithra.com/en/estetrol
ClinicalTrials.gov Identified NCT02817841
ClinicalTrials.gov Identified NCT02817828
Mithra Website: https://www.mithra.com/en/estetrol
ClinicalTrials.gov Identified NCT02817841
ClinicalTrials.gov Identified NCT02817828
Footnotes: - Pantarhei Bioscience is no longer involved in development.
- Pantarhei Bioscience is no longer involved in development.